Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nimustine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.35 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.34 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.34 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.34 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TKT | P29401 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nimustine SCHEMBL8414 | 0.99 | BLM (1.00) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL23301409 | 0.99 | BLM (1.00) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL1649545 | 0.98 | BLM (0.98) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL124427 | 0.98 | BLM (0.98) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL1649348 | 0.97 | BLM (0.96) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL1580335 | 0.95 | BLM (0.92) | BLMPMP22LMNANFKB1ALDH1A1 | |
| Nimustine SCHEMBL5886061 | 0.88 | BLM (0.80) | BLMPMP22LMNANFKB1ALDH1A1 | |
| SCHEMBL25299723 | 0.87 | LMNA (0.79) | BLMPMP22LMNANFKB1TKT | |
| SCHEMBL17524414 | 0.87 | BLM (0.79) | BLMPMP22LMNANFKB1ALDH1A1 | |
| SCHEMBL6541875 | 0.82 | LMNA (0.71) | BLMPMP22LMNANFKB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2271 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026041516-A1 | RESORBABLE SHEET MATERIAL COMPRISING POROUS COLLAGEN SPONGE AND NANOPARTICLES OR MICROPARTICLES WHICH RELEASE ACTIVE INGREDIENTS IN A CONTROLLED MANNER, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | MD2B LIFESCIENCE GMBH (DE) | 2026-02-26 | — | — | WO | claimed |
| WO-2025010213-A2 | MEDICAL CUTTING AND DRILL DEVICES HAVING STATIC COMPONENTS, RETRACTABLE SHEATHS, SENSORS, NAVIGATION COMPONENTS, WORKING BLADE BODIES, RAILS, STRUTS, CHANNELS FOR FLUID AND GAS FLOW, HAND-PIECE, ROBOTIC ARM ATTACHMENT CAPABILITIES, COMPUTING DEVICES, AND ASSOCIATED FEEDBACKS AND OUTPUTS | Innovations 4 Surgery, LLC (US) | 2025-01-09 | — | — | WO | claimed |
| US-20240416099-A1 | CONTROL OF EXOGENOUS AGENT CHARACTERISTICS IN MICROBUBBLE-MEDIATED ULTRASOUND PROCEDURES | INSIGHTEC LTD. (IL) | 2024-12-19 | — | — | US | claimed |
| WO-2024215445-A1 | CONVERGED MIXED REALITY (CMR): A LAYERED METADATA FRAMEWORK FOR MIXED REALITY ENHANCING WAYFINDING, NAVIGATION, AND COLLABORATION IN COMPLEX ENVIRONMENTS THROUGH TEXTURE SPACE ENCODING | GREUNKE LARRY CLAY (US) | 2024-10-17 | — | — | WO | claimed |
| US-12076520-B2 | Control of exogenous agent characteristics in microbubble-mediated ultrasound procedures | INSIGHTEC, LTD. (IL) | 2024-09-03 | — | — | US | claimed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | claimed |
| EP-3723856-B1 | CONTROL OF EXOGENOUS AGENT CHARACTERISTICS IN MICROBUBBLE-MEDIATED ULTRASOUND PROCEDURES | INSIGHTEC LTD (IL) | 2024-07-24 | — | — | EP | claimed |
| US-20240131362-A1 | Simulation-Based Drug Treatment Planning | INSIGHTEC, LTD. (IL) | 2024-04-25 | — | — | US | claimed |
| US-11938343-B2 | Cavitation-enhanced targeted drug delivery and dosing | INSIGHTEC, LTD. (IL) | 2024-03-26 | — | — | US | claimed |
| WO-2023235807-A2 | METHOD AND COMPOSITIONS FOR TREATING GLIOBLASTOMA WITH TRITERPENES | PHOENIX BIOTECHNOLOGY, INC. (US) | 2023-12-07 | — | — | WO | claimed |
| US-7071158-B2 | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS, INC. (US) | 2006-07-04 | — | — | US | claimed |
| CN-1160129-C | Process for preparing medicines with no or low loxic by-effect on gastrointestinal system | 王 晓 | 2004-08-04 | — | — | CN | claimed |
| US-20020010210-A1 | PHARMACEUTICAL PREPARATION AND METHOD FOR TREATING CANCER | SHOWA DENKO KABUSHIKI KAISHA (JP) | 2002-01-24 | — | — | US | claimed |
| US-20010049349-A1 | Antioxidant enhancement of therapy for hyperproliferative conditions | CRABTREE ACQUISITION CO, LLC | 2001-12-06 | — | — | US | claimed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0875246-A1 | Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1998-11-04 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0608546-A2 | Glia activating factor (GAF), antibodies against it and their uses | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-03 | — | — | EP | claimed |